scholarly journals Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case–control study

2010 ◽  
Vol 102 (9) ◽  
pp. 1415-1421 ◽  
Author(s):  
M C Bradley ◽  
C M Hughes ◽  
M M Cantwell ◽  
G Napolitano ◽  
L J Murray
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Nested Case Control ◽  
Control Study

scholarly journals Aspirin, Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and Pancreatic Cancer Risk: a Clinic-Based Case–Control Study

2011 ◽  
Vol 4 (11) ◽  
pp. 1835-1841 ◽  
Author(s):  
Xiang-Lin Tan ◽  
Kaye M. Reid Lombardo ◽  
William R. Bamlet ◽  
Ann L. Oberg ◽  
Dennis P. Robinson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Control Study

Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study

2016 ◽  
Vol 27 (12) ◽  
pp. 1457-1464 ◽  
Author(s):  
Pik Fang Kho ◽  
Jonathan Fawcett ◽  
Lin Fritschi ◽  
Harvey Risch ◽  
Penelope M. Webb ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Control Study

scholarly journals A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers

2006 ◽  
Vol 66 (20) ◽  
pp. 10213-10219 ◽  
Author(s):  
Rachael Z. Stolzenberg-Solomon ◽  
Reinhold Vieth ◽  
Azar Azad ◽  
Pirjo Pietinen ◽  
Philip R. Taylor ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Vitamin D ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Vitamin D Status ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

Statins and pancreatic cancer risk: a nested case–control study

2010 ◽  
Vol 21 (12) ◽  
pp. 2093-2100 ◽  
Author(s):  
Marie C. Bradley ◽  
Carmel M. Hughes ◽  
Marie M. Cantwell ◽  
Liam J. Murray
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study

scholarly journals DNA methylation derived immune cell profiles, CpG markers of inflammation, and pancreatic cancer risk

2020 ◽  
Author(s):  
Dominique S. Michaud ◽  
Mengyuan Ruan ◽  
Devin C. Koestler ◽  
Lola Alonso ◽  
Esther Molina-Montes ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dna Methylation ◽  
Cancer Risk ◽  
Case Control Study ◽  
Immune Cell ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Markers Of Inflammation ◽  
Nested Case Control ◽  
Control Study

AbstractPancreatic cancer is projected to become the second most common cause of cancer death over the next 5 years. Since inflammation is thought to be a common trajectory for disease initiation, we sought to prospectively characterize immune profiles using DNA methylation markers to examine whether they play a key role in pancreatic cancer risk. In a nested case-control study pooling three U.S. prospective cohort studies, DNA methylation was measured in prediagnostic leukocytes of incident pancreatic cancer cases and matched controls using the Illumina MethylationEPIC array. Differentially methylated regions were used to predict immune cell types and CpGs previously associated with blood inflammatory markers were selected for the analysis. DNA methylation data from a retrospective case-control study conducted in Spain (PanGenEU) was used for independent replication of results. Immune cell proportions and ratio of cell proportions were not associated with pancreatic cancer risk in the nested case-control study. Methylation extent of CpGs residing in or near gene MNDA was significantly associated with pancreatic cancer risk in the nested case-control study and replicated in PanGenEU. In the nested case-control study, the associations were present 10 or more years prior to cancer diagnosis. Methylation of a promoter CpG of gene PIM-1 was associated with pancreatic cancer survival in both studies. We identified several CpGs that may play a role in pancreatic carcinogenesis using a targeted approach for the selection of inflammation-based CpGs in two large, independent studies conducted in different countries with distinct study designs.

Assessing the effects of beta‐blockers on pancreatic cancer risk: A nested case‐control study

2020 ◽  
Vol 29 (5) ◽  
pp. 599-604
Author(s):  
Akram Saad ◽  
Jeffrey Goldstein ◽  
Ofer Margalit ◽  
Einat Shacham‐Shmueli ◽  
Yaacov R. Lawrence ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Risk ◽  
Case Control Study ◽  
Beta Blockers ◽  
Case Control ◽  
Pancreatic Cancer Risk ◽  
Nested Case Control ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document